Mdma Clinical Trials
Open-labeled Dose-extending Placebos as an Adjunct to Methadone Treatment: A Pilot Study
To see complete record on clinicaltrials.gov, please visit this link
Id: NCT02941809
Organisation Name: University of Maryland, Baltimore
Overal Status: Completed
Start Date: December 5, 2017
Last Update: August 11, 2020
Lead Sponsor: University of Maryland, Baltimore
Brief Summary: More than 2 million individuals in the United States have an Opioid Use Disorder (OUD). Methadone maintenance treatment is the gold standard of medication-assisted treatment for OUD, but high-dose methadone is associated with cardiotoxicity and respiratory complications, among other side effects. These adverse effects make enhancing the effectiveness of lower doses of methadone an attractive therapeutic goal. Long recognized for its capacity to enhance treatment outcomes for a wide range of neuropsychiatric disorders including pain, the placebo effect offers an as-yet untested avenue to such an enhancement. This approach is particularly compelling given that individuals with substance use disorder tend to have higher salience attribution, and may thereby be more sensitive to placebo effects. Our study combines two promising clinical methodologies-open-label placebo and conditioning-to investigate whether placebo effects can increase the effective potency of methadone in treatment-seeking OUD patients.
Conditions:
- Opioid-use Disorder
- Opioid-Related Disorders
Total execution time in seconds: 0.2132740020752